Cervikon - DIM vaginal suppositories 100mg, No. 25

Treatment of dysplasia (cervical intraepithelial neoplasia) of the cervix (regardless of the results of detecting papillomavirus infection by PCR).

Intravaginally, 100 mg 2 times a day. The duration of the course of treatment is 3-6 months. The duration of treatment is determined by the dynamics of clinical and laboratory parameters.
Recommendations for the method of administration of the drug:
The drug is injected into the vagina 2 times a day (morning and evening), 1 suppository. Hands should be thoroughly washed immediately before administration. The suppository is inserted deep into the vagina while lying down. After insertion, the use of a sanitary napkin is recommended.

active substance: diindolylmethane 100 mg;
excipients: solid fat (Witepsol N-15) (1.9795 g); crospovidone (Kollidone CL) (0.0200 g); dye carmine red, E 120 (0.0005 g).

Individual intolerance to any of the components of the drug.
The period of pregnancy and breastfeeding.
Children under the age of 18.

Trade name:

CerviconЃ-DIM

International non-proprietary or group name:

diindolylmethane.

Dosage form:

vaginal suppositories

Composition:

One suppository contains:

active substance: diindolylmethane 100 mg;
excipients: solid fat (Witepsol N-15) (1.9795 g); crospovidone (Kollidone CL) (0.0200 g); dye carmine red, E 120 (0.0005 g).

Description:

Suppositories from light pink to yellowish pink, torpedo shape.

Pharmacotherapeutic group:

other antineoplastic drugs

ATX code:

L01XX

Pharmacological properties

Pharmacodynamics
The drug CervikonЃ-DIM contains diindolylmethane as an active ingredient, which is an agent that stimulates the apoptosis of human papillomavirus (HPV) and transformed cells, as well as a stimulator of the expression of receptors for ?-interferon. Thus, the therapeutic effect of diindolylmethane is based on its ability to accelerate the elimination of human papillomavirus-infected and transformed cells and to enhance the nonspecific immune response to infection. In addition, diindolylmethane normalizes the metabolism of estradiol in HPV-infected cells, preventing the formation of a carcinogenic metabolite of estrogen (16?-hydroxyestrone), which stimulates the expression of HPV oncogenes. By suppressing the expression of the E7 oncogene of the human papillomavirus,diindolylmethane blocks hormone-dependent pathological proliferation of HPV-infected cells.
Diindolylmethane belongs to practically non-toxic drugs (LD50 more than 5 g / kg).
Pharmacokinetics
With intravaginal administration, diindolylmethane has a high local bioavailability and practically does not enter the systemic circulation.

Indications for use

Treatment of dysplasia (cervical intraepithelial neoplasia) of the cervix (regardless of the results of detecting papillomavirus infection by PCR).

Contraindications

Individual intolerance to any of the components of the drug.
The period of pregnancy and breastfeeding.
Children under the age of 18.

Application during pregnancy and during breastfeeding

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Method of administration and recommended doses

Intravaginally, 100 mg 2 times a day. The duration of the course of treatment is 3-6 months. The duration of treatment is determined by the dynamics of clinical and laboratory parameters.
Recommendations for the method of administration of the drug:
The drug is injected into the vagina 2 times a day (morning and evening), 1 suppository. Hands should be thoroughly washed immediately before administration. The suppository is inserted deep into the vagina while lying down. After insertion, the use of a sanitary napkin is recommended.

Overdose

Overdose symptoms are unknown.

Interaction with other medicinal products

Has not been studied. Due to the lack of systemic pharmacokinetics, no interactions with systemic drugs are expected. The drug should not be used concurrently with local preparations for intravaginal use belonging to the group of antiseptic-oxidizing agents (potassium permanganate, iodine, hydrogen peroxide).

special instructions

When treating vaginal infections, the drug should not be used during menstruation; it is advisable to start treatment after menstruation. During the treatment period, it is recommended to refrain from sexual intercourse. It is recommended to use contraceptives during treatment.

Influence on the ability to drive vehicles and mechanisms

CerviconЃ-DIM does not affect the ability to control vehicles and mechanisms.

Release form

Vaginal suppositories, 100 mg.
5 or 10 suppositories in a blister made of polyvinyl chloride film.
2, 3, 5, 7, 9 blisters No. 5, together with instructions for use, are placed in a cardboard box.
2, 3, 4, 5, 6, 7, 8, 9, 10 blisters No. 10, together with instructions for use, are placed in a cardboard box.

Storage conditions

In a dark place at a temperature of 2 ? C to 8 ? C.
Keep out of the reach of children.

Shelf life

2 years. Do not use the drug after the expiration date.

Vacation conditions:

On prescription.